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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objectives will be to assess the benefits and harms of beta-blockers alone or with endoscopic therapy for prevention of rebleeding
in patients with oesophageal varices.
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B A C K G R O U N D
Varices are present in 30% of patients with cirrhosis and in 60%
of patients with cirrhosis and ascites (D’Amico 1997; Tripathi
2001). Variceal bleeding occurs in one-third of these patients with
mortality of 50% (Tripathi 2001). Patients with portal hyperten-
sion who have bled from oesophageal varices have a high risk of
rebleeding. The risk is 60% to 70% at one year if no preven-
tive therapy is instituted (Bernard 1997; Bernard-Chabert 2004).
Predictors of recurrent bleeding include bleeding on endoscopy,
large oesophageal varices, severity of index bleed, severity of portal
hypertension as determined by hepatic venous pressure gradient
(HVPG)measurement and presence of encephalopathy, ascites, or
renal impairment (Gluud 1988; de Franchis 1992; Zaman 2005).
Since there is a high risk of recurrence of variceal haemorrhage,
patients should be offered secondary prophylaxis to prevent re-
bleeding.
Drugs, endoscopic modes of treatment, surgery, or transjugular
intrahepatic portosystemic shunt are used for prevention of recur-
rent variceal haemorrhage (Zaman 2005). Drug therapy in por-
tal hypertension is administered to normalize the increased por-
tal blood inflow by using beta-blockers or isosorbide mononi-
trate. Beta-blockers (propranolol or nadolol) are the most effec-
tive agents for prevention of variceal rebleeding (Tripathi 2001).
Addition of isosorbide mononitrate increases the efficacy of beta-
blockers (Tripathi 2001). The therapeutic goals of drug therapy
are to attain reduction in HVPG to 20% of baseline value or to 12
mm Hg to prevent or reduce the risk of rebleeding from varices (
Groszmann 1990; Feu 1995; D’Amico 2006). Achieving a reduc-
tion in HVPG to 12 mm Hg or to 20% of baseline value is used
for labelling responders. Patients not showing reduction inHVPG
of this degree are called nonresponders. With drug therapy, about
45% to 63% of patients are non-responders. Non-responders with
recurrence of variceal haemorrhage on drug therapy are 46% to
65%compared to 7% to 13% of responders (Zaman 2005). It has
been found that the haemodynamic response to drug therapy in
terms of the reduction inHVPG is stable during long-term follow-
up (Villanueva 2004).
Randomised trials, meta-analyses, and narrative reviews have
found that beta-blockers are effective in prevention of variceal re-
bleeding (Hayes 1990; D’Amico 1995; Bernard 1997; Tripathi
2001; Zaman 2005). However, the estimated effects in different
trials vary, possibly depending on the treatment strategy or con-
trol of bias in the individual trials. Furthermore, a number of en-
doscopic treatments including sclerotherapy and banding ligation
are increasingly used to prevent rebleeding. Hence, it is important
to assess whether the use of concomitant endoscopic therapy af-
fects the effect of beta-blockers on the risk of rebleeding and mor-
tality. The question has been assessed in a number of trials, but
the results are equivocal. We, therefore, will perform a Cochrane
systematic review on the beneficial and harmful effects of beta-
blockers without or with concomitant endoscopic therapy for pre-
vention of rebleeding from oesophageal varices.
O B J E C T I V E S
The objectives will be to assess the benefits and harms of beta-
blockers alone or with endoscopic therapy for prevention of re-
bleeding in patients with oesophageal varices.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised clinical trials irrespective of blinding,
publication status, or language.
Types of participants
Patients with oesophageal varices and a history of upper gastroin-
testinal bleeding, likely to be variceal in origin will be included
irrespective of the aetiology of portal hypertension, ie, cirrhosis or
other liver disease.
Types of interventions
We will perform the following comparisons:
- Beta-blockers versus no intervention or placebo.
- Beta-blockers plus sclerotherapy versus sclerotherapy.
- Beta-blockers plus band ligation versus band ligation.
Types of outcome measures
Primary outcome measure
(1) Rebleeding diagnosed by endoscopy or identification of hae-
matemesis, melena, or gastric aspirate containing blood.
(2) All-cause mortality.
Secondary outcome measures
(3) Rebleeding-related mortality.
(4) Adverse events defined as any untoward medical occurrence
not necessarily having a causal relationship with the treatment, but
resulting in a dose reduction or discontinuation of the intervention
(ICH-GCP 1997).
(5) Quality-of-life measures (as reported by authors).
(6) Obliteration and recurrence of oesophageal varices after endo-
scopic therapy.
All outcome measures will be assessed at the maximum follow-up
in the individual trials.
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Search methods for identification of studies
We will search for eligible trials in The Cochrane Hepato-Biliary
Group Controlled Trials Register, the Cochrane Central Register of
Controlled Trials in The Cochrane Library, MEDLINE, EMBASE,
and Science Citation Index Expanded (Royle 2003). All searches
will be performed using the electronic search strategies described
in Appendix 1. Additional trials will be identified through scan-
ning of reference lists in relevant papers and conference proceed-
ings and through correspondence with experts and pharmaceuti-
cal companies.
Data collection and analysis
We will follow the instructions given in the Cochrane Handbook
for Systematic Reviews of Intervention (Higgins 2005) and The
Cochrane Hepato-Biliary Group Module (Gluud 2006).
One author (BCS) will perform the searches. Two authors (BCS
and SKS) will decide on inclusion of trials and extract data in-
dependently. One author (LLG) will validate the extracted data.
Disagreements will be resolved through discussion. Excluded tri-
als will be listed with the reason for exclusion. Primary authors of
the included trials will be contacted for additional information if
outcome measures are not included in the published trial reports.
The methodological quality will be defined as the control of bias
in the individual trials. Allocation sequence generation, allocation
concealment, blinding, and follow-upwill be extracted asmeasures
of bias control (Gluud 2001; Kjaergard 2001) using the following
definitions:
Generation of the allocation sequence
• adequate (computer generated random numbers, table of
random numbers, or similar);
• unclear (the trial was described as randomised, but the
generation of the allocation sequence was not described); or
• inadequate (quasi-randomised trials).
Allocation concealment
• adequate (concealed up to the point of treatment by central
randomisation, sealed envelopes, or similar);
• unclear (the allocation concealment was not described); or
• inadequate (open table of random numbers or similar).
Trials in which the allocation sequence generation or allocation
concealment was inadequate (ie, using allocation systems based
on dates, names, admittance numbers, or similar) will be excluded
from the present review.
Blinding
• Adequate an identical placebo was used to achieve blinding.
Trials will be classified as single or double blind using the descrip-
tions provided in the individual trial reports. Data on whether
patients or investigators (eg, health-care providers, outcome asses-
sors, or data analysis) were blinded will also be extracted.
Follow-up
The number and reasons for losses to follow-up will be extracted
to assess the risk of attrition bias. We will also extract whether a
pre-planned sample size calculation was performed and whether
the planned sample size was reached.
From the individual trials, we will also extract data on the baseline
characteristics of patients (inclusions criteria, mean age, sex, and
number of patients with cirrhosis), treatments (type and dose of
therapy), and trials (country of origin, publication status, funding,
duration of follow-up, and all outcomes).
Statistical analyses
The analyses will be performed in RevMan (RevMan 2003) and
STATA version 8.0 for Windows. Results of the meta-analyses
will be presented as relative risks (RR) with 95% confidence in-
tervals (95% CI). Random-effects models will be used in the pri-
mary analyses because of the expected clinical heterogeneity. Chi-
squared analyses will be performed to estimate inter-trial hetero-
geneity. All analyses will be performed using the intention-to-treat
principle including all randomised patients irrespective of compli-
ance or follow-up. For patients with missing data, carry forward of
the last observed response will be used. Sensitivity analyses assess-
ing potential sources of heterogeneity and bias included random-
effectmeta-regression, worst-case scenario analyses, and regression
analyses of funnel plots. To achieve themaximum statistical power
in the sensitivity analyses, all trials will be combined. The outcome
measures assessed in the meta-regression will include rebleeding
and mortality. Fixed-effect subgroup meta-analyses will be per-
formed for significant predictors identified in themeta-regression.
In the worst-case scenario analyses, patients with missing data will
be counted as treatment failures to assess the risk of attrition bias.
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A P P E N D I C E S
Appendix 1. Search Strategies
Database Date of search Search terms
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
Date will be given at review stage. (beta-blocker* OR ’adrenergic beta antagonist*’)
AND (’variceal rebleeding’ OR (recurren* AND
variceal AND(bleedingORhemorrhage))OR ’sec-
ondary prophylaxis of variceal bleeding’)
Cochrane Central Register of Controlled
Trials (CENTRAL) in The Cochrane Li-
brary
Latest issue. #1 MeSH descriptor Adrenergic beta-Antagonists
explode all trees
#2 beta-blocker* or adrenergic beta antagonist*
#3 (#1 OR #2)
#4 MeSH descriptor Esophageal and Gastric
Varices explode all trees
#5 variceal rebleeding or (recurren* and variceal
and (bleeding or hemorrhage)) or secondary pro-
phylaxis of variceal bleeding
#6 (#4 OR #5)
#7 (#3 AND #6)
MEDLINE (WinSPIRS 5.0) 1950 to date search is performed. #1 explode “Adrenergic-beta-Antagonists”/all sub-
headings
#2 beta-blocker* or adrenergic beta antagonist*
#3 #1 or #2
#4 explode “Esophageal-and-Gastric-Varices”/all
subheadings
#5 variceal rebleeding or (recurren* and variceal
and (bleeding or hemorrhage)) or secondary pro-
phylaxis of variceal bleeding
#6 #4 or #5
#7 #3 and #6
#8 random* or blind* or placebo* or meta-analysis
#9 #7 and #8
EMBASE (WinSPIRS 5.0) 1980 to date search is performed #1 explode “beta-adrenergic-receptor-blocking-
agent”/all subheadings
#2 beta-blocker* or adrenergic beta antagonist*
#3 #1 or #2
#4 explode “esophagus-varices”/all subheadings
#5 variceal rebleeding or (recurren* and variceal
and (bleeding or hemorrhage)) or secondary pro-
phylaxis of variceal bleeding
#6 #4 or #5
#7 #3 and #6
#8 random* or blind* or placebo* or meta-analysis
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(Continued)
#9 #7 and #8
Science Citation Index Expanded
(http://portal.isiknowledge.com/
portal.cgi?DestApp=WOS&Func=Frame)
1945 to date search is performed. #5 #4 AND #3
#4 TS=(random* or blind* or placebo* or meta-
analysis)
#3 #2 AND #1
#2 TS=(variceal rebleeding or (recurren* and
variceal and (bleeding or hemorrhage)) or sec-
ondary prophylaxis of variceal bleeding)
#1 TS=(beta-blocker* OR adrenergic beta antago-
nist*)
WH A T ’ S N E W
22 October 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 2, 2007
C O N T R I B U T I O N S O F A U T H O R S
BCS drafted the protocol and will draft the review. LLG and SKS revised the protocol and will revise the review. All authors approved
of the final version of the protocol.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
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